title: A prospective feasibility trial investigating the use of the Impella 2.5 system in patients undergoing high-risk percutaneous coronary intervention (The PROTECT I Trial): initial U.S. experience.
abstract: OBJECTIVE
  We sought to evaluate the safety and feasibility of the Impella 2.5 system (Abiomed Inc., Danvers, Massachusetts) in patients undergoing high-risk percutaneous coronary intervention (PCI).
  
  
  BACKGROUND
  The Impella 2.5 is a miniaturized percutaneous cardiac assist device, which provides up to 2.5 l/min forward flow from the left ventricle into the systemic circulation.
  
  
  METHODS
  In a prospective, multicenter study, 20 patients underwent high-risk PCI with minimally invasive circulatory support employing the Impella 2.5 system. All patients had poor left ventricular function (ejection fraction <or=35%) and underwent PCI on an unprotected left main coronary artery or last patent coronary conduit. Patients with recent ST-segment elevation myocardial infarction or cardiogenic shock were excluded. The primary safety end point was the incidence of major adverse cardiac events at 30 days. The primary efficacy end point was freedom from hemodynamic compromise during PCI (defined as a decrease in mean arterial pressure below 60 mm Hg for >10 min).
  
  
  RESULTS
  The Impella 2.5 device was implanted successfully in all patients. The mean duration of circulatory support was 1.7 +/- 0.6 h (range: 0.4 to 2.5 h). Mean pump flow during PCI was 2.2 +/- 0.3 l/min. At 30 days, the incidence of major adverse cardiac events was 20% (2 patients had a periprocedural myocardial infarction; 2 patients died at days 12 and 14). There was no evidence of aortic valve injury, cardiac perforation, or limb ischemia. Two patients (10%) developed mild, transient hemolysis without clinical sequelae. None of the patients developed hemodynamic compromise during PCI.
  
  
  CONCLUSIONS
  The Impella 2.5 system is safe, easy to implant, and provides excellent hemodynamic support during high-risk PCI. (The PROTECT I Trial; NCT00534859).
authors.affiliation: William Beaumont Hospital, Royal Oak, Michigan, USA.
authors.forename: Simon R
authors.initials: SR
authors.lastname: Dixon
authors.forename: José P S
authors.initials: JP
authors.lastname: Henriques
authors.forename: Laura
authors.initials: L
authors.lastname: Mauri
authors.forename: Krischan
authors.initials: K
authors.lastname: Sjauw
authors.forename: Andrew
authors.initials: A
authors.lastname: Civitello
authors.forename: Biswajit
authors.initials: B
authors.lastname: Kar
authors.forename: Pranav
authors.initials: P
authors.lastname: Loyalka
authors.forename: Frederic S
authors.initials: FS
authors.lastname: Resnic
authors.forename: Paul
authors.initials: P
authors.lastname: Teirstein
authors.forename: Raj
authors.initials: R
authors.lastname: Makkar
authors.forename: Igor F
authors.initials: IF
authors.lastname: Palacios
authors.forename: Michael
authors.initials: M
authors.lastname: Collins
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Moses
authors.forename: Karim
authors.initials: K
authors.lastname: Benali
authors.forename: William W
authors.initials: WW
authors.lastname: O'Neill
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000295:instrumentation / Q000706:statistics & numerical data*; D015992:Body Mass Index; D003324:Coronary Artery Disease / Q000628:therapy*; D005240:Feasibility Studies; D005260:Female; D006439:Hemodynamics; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D013318:Stroke Volume; D014481:United States; D016277:Ventricular Function, Left